Phylex Biosciences has achieved positive results with its new mRNA nanoparticle vaccine against the Nipah virus in an immunogenicity study conducted in collaboration with scientists of the U.S. Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia.
The Nipah virus is a pathogen causing encephalitis and acute respiratory distress in humans, with recent outbreaks in Bangladesh, India, Malaysia, the Philippines and Singapore, and a fatality rate over 50%. The natural hosts of the virus are large fruit bats present across South Asia. Last month the Indian state of Kerala reported the death of a 14-year-old boy from a Nipah virus infection. To date, no approved vaccine or therapeutic exists against the Nipah virus.
Phylex has published a preprint of a research article on immunogenicity of its Nipah mRNA nanoparticle vaccine candidate in mice co-authored with scientists of the CDC. The vaccine elicited a robust neutralizing antibody response, with neutralizing titers markedly higher than with several other Nipah vaccine designs, and efficient neutralizing even with a single dose.
The Phylex mRNA vaccine encodes for a nanoparticle displaying 60 copies of the antigen based upon the head domain of the G protein of the Nipah virus. In virus neutralization assays, neutralization titers of Phylex vaccine-elicited sera against Nipah virus were 3-fold the average titers of 14 individuals in Bangladesh who survived a Nipah virus infection.
“We are grateful to our co-authors at the CDC for their contribution in assessing our vaccine against this difficult pathogen,” said Pascal Brandys, co-founder and CEO of Phylex Biosciences. “The results confirm the strong advantage of our mRNA vaccine encoding for a highly immunogenic nanoparticle, as compared with a variety of other technologies.”
“Our vaccine combines the advantages of mRNA for speed of manufacturing and development and a nanoparticle for efficacy after one dose,” Brandys continued. “We will aggressively pursue the clinical development of our vaccine candidate to initiate clinical trials with exposed individuals on a compassionate basis and save lives as soon as possible.”
About Phylex BioSciences
Founded at the beginning of the COVID-19 pandemic by genomics pioneer Pascal Brandys and virologist Jens Herold, Phylex BioSciences is the first company to pursue the development of a mRNA nanoparticle vaccine against the Nipah virus.
https://www.prnewswire.com/news-releases/phylex-vaccine-on-track-to-combat-deadly-nipah-virus-with-positive-results-of-immunogenicity-study-302215366.html
Check out our mRNA service to expedite your vaccine research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Skyline Therapeutics Receives FDA Orphan Drug Designation for Gene Therapy for Retinitis Pigmentosa
BOSTON & SHANGHAI, September 2, 2024 – Skyline Therapeutics, a gene therapy company focused on innovative treatments for rare and severe diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for SKG1108....
Novavax Receives Emergency Use Authorization for Updated Covid-19 Vaccine
Novavax has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its updated Covid-19 vaccine, NVX-CoV2705, joining other vaccine manufacturers in addressing evolving virus variants. The EUA permits the use of Novavax's...
Turn Biotechnologies Reports Historic Skin Cell Rejuvenation Breakthroughs at ESDR this Week
Company will present data from its successful rejuvenation of fibroblasts and keratinocytes to influential gathering of international dermatologists MOUNTAIN VIEW, Calif., Sept. 4, 2024 /PRNewswire/ -- Turn Biotechnologies, a developer of novel mRNA medicines and...
H5 influenza vaccines: What needs to be done to reduce the risk of a pandemic
As the global threat of H5N1 influenza looms with outbreaks across species and continents including the U.S., three international vaccine and public health experts say it is time to fully resource and support a robust strategy to address this and future potential...
Related Services
Plasmids GMP Services
AAV GMP Services
